Mindray and Tencent AI Lab to Jointly Develop AI Products for Blood Disease Screening and In Vitro Diagnosis
|
By LabMedica International staff writers Posted on 04 Mar 2021 |

Illustration
Shenzhen Mindray Biomedical Electronics Co., Ltd. (Shenzhen, China) has signed an AI cooperation framework agreement with Tencent AI Lab (Shenzhen, China) to jointly develop AI products for blood cell analysis and further explore AI technology in vitro diagnostics.
Through this cooperation, the two parties will further develop blood cell morphology testing equipment and system applications with world-class imaging quality and cell recognition capabilities. Large-scale production in the future is expected to relieve the work pressure faced by primary endoscopy physicians, and improve the diagnosis and diagnosis of blood diseases.
Tencent AI Lab will use machine learning, computer vision and other cutting-edge algorithms and the experience of its research scientists, Tencent Cloud’s comprehensive solutions, combined with Mindray Medical’s expertise in slide processing, imaging systems, integrated design, and clinical experts, massive data and other aspects, to jointly develop an automated blood cell analyzer in order to further improve accuracy in results. The automated blood cell analyzer will detect cell quality changes and have high levels of cell identification capability. At the same time, it will provide a cost advantage as compared to rival products with higher prices.
In addition to morphological testing, Tencent AI Lab will also work with Mindray Medical to explore the integration and application of AI technology in other areas of in vitro diagnostics, such as urine analysis, smart laboratory, and in vitro diagnostic big data, in order to provide better quality medical equipment and services.
“AI+Medical/Pharmaceutical" is one of Tencent's AI Lab's long-term core research directions. We are very happy to cooperate with industry top partners like Mindray to enable technology to help medical care, assist doctors, and serve patients,” said Yang Wei, General Manager of Tencent AI Lab.
“With Mindray’s deep understanding of clinical needs and accumulation of detection technology over the years, and Tencent’s leading exploration in artificial intelligence technology, The results of the cooperation between the two parties will greatly improve the ability of clinical intelligent detection,” said Yan Huawen, General Manager of Mindray’s IVD Division.
Related Links:
Mindray
Tencent AI Lab
Through this cooperation, the two parties will further develop blood cell morphology testing equipment and system applications with world-class imaging quality and cell recognition capabilities. Large-scale production in the future is expected to relieve the work pressure faced by primary endoscopy physicians, and improve the diagnosis and diagnosis of blood diseases.
Tencent AI Lab will use machine learning, computer vision and other cutting-edge algorithms and the experience of its research scientists, Tencent Cloud’s comprehensive solutions, combined with Mindray Medical’s expertise in slide processing, imaging systems, integrated design, and clinical experts, massive data and other aspects, to jointly develop an automated blood cell analyzer in order to further improve accuracy in results. The automated blood cell analyzer will detect cell quality changes and have high levels of cell identification capability. At the same time, it will provide a cost advantage as compared to rival products with higher prices.
In addition to morphological testing, Tencent AI Lab will also work with Mindray Medical to explore the integration and application of AI technology in other areas of in vitro diagnostics, such as urine analysis, smart laboratory, and in vitro diagnostic big data, in order to provide better quality medical equipment and services.
“AI+Medical/Pharmaceutical" is one of Tencent's AI Lab's long-term core research directions. We are very happy to cooperate with industry top partners like Mindray to enable technology to help medical care, assist doctors, and serve patients,” said Yang Wei, General Manager of Tencent AI Lab.
“With Mindray’s deep understanding of clinical needs and accumulation of detection technology over the years, and Tencent’s leading exploration in artificial intelligence technology, The results of the cooperation between the two parties will greatly improve the ability of clinical intelligent detection,” said Yan Huawen, General Manager of Mindray’s IVD Division.
Related Links:
Mindray
Tencent AI Lab
Latest Industry News
- QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools
- Partnership Expands Ultrasensitive Blood-Based Diagnostics for Hematologic Malignancies
- Genetic Testing Program Expands Detection of Alpha-1 Antitrypsin Deficiency
- Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
- Open-Source Consortium Aims to Standardize Digital Pathology Workflows
- Diazyme Laboratories Acquires Carolina Liquid Chemistries
- Partnership Expands Access to Alzheimer’s Blood Tests in Latin America and Caribbean
- Global Multiplex Assays Market Driven by High-Throughput Diagnostic Demand
- GRAIL Presents Full Results from NHS-Galleri Trial at ASCO 2026
- Global Framework Integrates Digital Pathology for Companion Diagnostic Development
- Werfen and Oxford Nanopore Collaborate on Transplant Assay Development
- New Distribution Agreement Expands Access to CE-Marked Precision Oncology Assays
- ClearNote Health to Present Pancreatic Cancer Blood Test Data at ASCO 2026
- Artera to Highlight AI-Based Cancer Risk Stratification at ASCO 2026
- Natera to Present Data on MRD-Guided Cancer Care at ASCO 2026
- Fujifilm Integrates Structured Reporting into Digital Pathology Workflow
Channels
Clinical Chemistry
view channel
Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth
Preterm and early-term births can lead to lasting complications because vital organs continue to mature during the final weeks of pregnancy. Babies born too soon face increased risks of breathing difficulties,... Read more
Blood-Based Alzheimer’s Testing Platform Offers Rapid Results
Accurate identification of Alzheimer’s disease pathology often relies on cerebrospinal fluid analysis or positron emission tomography, which can be invasive, costly, and not widely accessible.... Read more
Simple Oral Swab Monitors Persistent Inflammation in Primary Ciliary Dyskinesia
Primary ciliary dyskinesia is a rare lung disease that affects about one in 7,500 to 10,000 live births worldwide. Symptoms can begin in the newborn period and progress to recurrent respiratory infections... Read more
Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features
Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read moreMolecular Diagnostics
view channel
Spatial Map Guides Treatment Selection in Muscle-Invasive Bladder Cancer
Muscle-invasive bladder cancer is clinically heterogeneous, with patients often responding very differently to therapy. Existing biomarkers do not fully explain these disparities, limiting precision treatment... Read more
Genomic Study Identifies Risk Regions for Intrahepatic Cholestasis of Pregnancy
Intrahepatic cholestasis of pregnancy (ICP) affects 0.2–2% of pregnancies and typically arises after 30 weeks, presenting with intense itching of the palms and soles. Diagnosis is confirmed by elevated... Read more
Point-of-Care PCR Panel Detects RSV, Influenza, and SARS-CoV-2 in Minutes
Respiratory syncytial virus, influenza, and SARS-CoV-2 remain major respiratory pathogens in ambulatory care. RSV is a particular priority because it can cause significant disease in infants, older adults,... Read more
Whole-Genome Sequencing Enables Genetic Diagnosis in Neurodevelopmental Disorders
Neurodevelopmental disorders include autism spectrum disorder and intellectual disability and can be difficult to diagnose because clinical presentations vary widely. In Italy, approximately 1% of children... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Lab-on-a-Chip Approach Advances Immune–Cancer Cell Interaction Analysis
Conventional cytotoxicity assays often average responses across thousands of cells, obscuring how individual immune cells engage and kill tumor cells. For immunotherapy evaluation, the precise sequence... Read more
Antibody Profiles Provide Clues to Long COVID Severity and Symptoms
Persistent symptoms after acute COVID-19 affect millions of people, causing fatigue, respiratory issues, and cognitive deficits that can be difficult to quantify with standard tests. Clinical teams lack... Read moreMicrobiology
view channel
Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
Melioidosis, a potentially fatal infection caused by Burkholderia pseudomallei, remains difficult to recognize because its symptoms can mimic tuberculosis and other illnesses. The disease is considered... Read more
Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
Helicobacter pylori infects an estimated 43.9% of the global population, affecting approximately 4.4 billion people worldwide. In many regions, including Africa, Eastern Europe, and Southeast Asia, prevalence... Read more
Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read morePathology
view channel
Stain-Free Imaging Platform Matches Standard Cancer Pathology
Histopathology underpins cancer diagnosis, but turnaround times and inter-laboratory variability can limit timely, consistent interpretation. Conventional staining relies on chemical dyes and multiple... Read more
New Companion Diagnostic Expands Precision Medicine in Prostate Cancer
Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more








